Optimization of thienopyrrole-based finger-loop inhibitors of the hepatitis C virus NS5B polymerase (Q27656967)

13

0 references

author name string

Jose Ignacio Martin Hernando

1

0 references

Jesus Maria Ontoria

2

0 references

Savina Malancona

3

0 references

Barbara Attenni

4

0 references

Fabrizio Fiore

5

0 references

Fabio Bonelli

6

0 references

Uwe Koch

7

0 references

Stefania Di Marco

8

0 references

Stefania Colarusso

9

0 references

Simona Ponzi

10

0 references

Nadia Gennari

11

0 references

Sue Ellen Vignetti

12

0 references

Jörg Habermann

14

0 references

Michael Rowley

15

0 references

Frank Narjes

The scientific challenge of hepatitis C.

16

0 references

publication date

October 2009

0 references

published in

ChemMedChem

0 references

volume

4

0 references

issue

10

0 references

page(s)

1695-713

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Hepatitis C: an update on the silent epidemic

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

The way forward in HCV treatment--finding the right path

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Challenges and successes in developing new therapies for hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Control of hepatitis C: a medicinal chemistry perspective

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Inhibitors of hepatitis C virus polymerase: synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

The discovery of pyrano[3,4-b]indole-based allosteric inhibitors of HCV NS5B polymerase with in vivo activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Development of carboxylic acid replacements in indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Binding mode determination of benzimidazole inhibitors of the hepatitis C virus RNA polymerase by a structure and dynamics strategy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: from benzimidazole to indole scaffolds.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Tetracyclic indole inhibitors of hepatitis C virus NS5B-polymerase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Discovery of pentacyclic compounds as potent inhibitors of hepatitis C virus NS5B RNA polymerase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Preclinical pharmacokinetics and metabolism of a potent non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Identification of thieno[3,2-b]pyrroles as allosteric inhibitors of hepatitis C virus NS5B polymerase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021

Rapid chromatographic technique for preparative separations with moderate resolution

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200900184

7 January 2021